Aktienanalyse zu AptarGroup, Inc. (ATR)ATRAptarGroup, Inc.

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).

AptarGroup Inc is a good buy right now due to its recent strong earnings report, which showed a non-GAAP EPS of $1.42, beating expectations by $0.07, and a revenue growth of 6.6% year-over-year to $1.03 billion. Additionally, the forward P/E ratio of 17.54 suggests that the stock is relatively undervalued compared to its growth potential. However, the RSI of 41.17 indicates that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent 5-day price change of -1.34%, indicating short-term volatility.

9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.